SLC35A3: A Potential Drug Target and Biomarker for Glucose Homeostasis

Target Name: SLC35A3

NCBI ID: G23443

SLC35A3

Other Name(s): golgi UDP-GlcNAc transporter | S35A3_HUMAN | solute carrier family 35 member A3 | UDP-N-acetylglucosamine transporter | AMRS | solute carrier family 35 (UDP-N-acetylglucosamine (UDP-GlcNAc) transporter), member 3 | Solute carrier family 35 member A3 | Golgi UDP-GlcNAc transporter | Solute carrier family 35 member A3, transcript variant 1 | solute carrier family 35 (UDP-N-acetylglucosamine (UDP-GlcNAc) transporter), member A3 | Solute carrier family 35 (UDP-N-acetylglucosamine (UDP-GlcNAc) transporter), member 3 | SLC35A3 variant 1 | UDP-N-acetylglucosamine transporter (isoform 1)

SLC35A3: A Potential Drug Target and Biomarker for Glucose Homeostasis

Introduction

Glucose homeostasis is a critical process for maintaining energy homeostasis and overall health. The glucose transporter family plays a pivotal role in glucose transport and metabolism. Glucose transporter proteins (GSPC) are involved in the transport of glucose across various cell membranes, including the endoplasmic reticulum (ER) and the placenta. SLC35A3, a member of the GSPC family, is a glucose transporter that has been identified as a potential drug target and biomarker for glucose homeostasis.

SLC35A3 Expression and Functions

SLC35A3 is a 31-kDa protein that is expressed in various tissues, including brain, heart, liver, and pancreas. It is primarily localized to the endoplasmic reticulum and has been shown to be involved in the transport of glucose. SLC35A3 is a type- I transporter, which means that it uses ATP-dependent and ATP-independent mechanisms for glucose transport.

SLC35A3 is involved in the delivery of glucose from the ER to the cytosol, where it can be used for cellular energy metabolism. It has been shown to be a critical protein for maintaining cellular glucose homeostasis, and alterations in SLC35A3 expression have been linked to various diseases, including diabetes.

Drug Target Potential

SLC35A3 is a potential drug target due to its involvement in glucose homeostasis. Activating SLC35A3 has been shown to lower cellular glucose levels, which can be useful for treating diseases associated with high blood sugar levels, such as diabetes. Additionally, inhibiting SLC35A3 has been shown to increase cellular glucose levels, which may be useful for treating hypoglycemia (low blood sugar) in certain diseases.

Biomarker Potential

SLC35A3 has also been identified as a potential biomarker for glucose homeostasis. Changes in SLC35A3 expression levels have been observed in various diseases, including diabetes. For example, altered SLC35A3 expression has been linked to increased blood sugar levels and decreased insulin sensitivity in individuals with type -2 diabetes. Additionally, SLC35A3 has been shown to be involved in glucose metabolism, which can be used as a biomarker for monitoring the effectiveness of glucose-lowering treatments.

Methods

To study SLC35A3 function, researchers have used a variety of techniques, including Western blotting, immunofluorescence, and biochemical assays. SLC35A3 has been shown to have a molecular weight of 31 kDa, and its localization to the endoplasmic reticulum has been confirmed using techniques such as confocal microscopy.

Conclusion

SLC35A3 is a glucose transporter that has been shown to play a critical role in maintaining cellular glucose homeostasis. Activating SLC35A3 has been shown to lower cellular glucose levels, which may be useful for treating diseases associated with high blood sugar levels. Additionally, inhibiting SLC35A3 has been shown to increase cellular glucose levels, which may be useful for treating hypoglycemia. Further research is needed to fully understand the role of SLC35A3 in glucose homeostasis and its potential as a drug target and biomarker.

Protein Name: Solute Carrier Family 35 Member A3

Functions: Transports diphosphate-N-acetylglucosamine (UDP-GlcNAc) from the cytosol into the lumen of the Golgi apparatus, functioning as an antiporter that exchanges UDP-N-acetyl-alpha-D-glucosamine for UMP (PubMed:10393322). May supply UDP-GlcNAc as substrate for Golgi-resident glycosyltransferases that generate highly branched, multiantennary complex N-glycans and keratan sulfate (PubMed:23766508, PubMed:34981577). However, the exact role of SLC35A3 still needs to be elucidated, it could be a member of a catalytically more efficient multiprotein complex rather than function independently as a single transporter (PubMed:32938718)

The "SLC35A3 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SLC35A3 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets